MOUNTAIN VIEW, Calif. (AP) ¿ Drugmaker Vivus Inc. says it plans to report results from two late-stage studies of its obesity drug candidate Qnexa Wednesday morning.

The company said it will post the results from the EQUIP and CONQUER studies at 6 a.m., with a conference call to discuss the data at 8 a.m. Vivus reported two successful midstage trials in June, saying Qnexa helped type 2 diabetes patients lower their blood sugar levels and lose weight.

Vivus shares rose 52 cents, or 8.1 percent in Tuesday regular trading, finishing at $6.91. In the aftermarket session, the stock jumped $1.34, or 19.4 percent, to $8.25.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.